Photohyperthermal therapy using liposomally formulated indocyanine green for feline nasal lymphoma: A case report.
drug delivery system
feline lymphoma
indocyanine green
liposome
photohyperthermal therapy
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
07
05
2019
accepted:
05
06
2020
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
ppublish
Résumé
Our previous research has focused on the development of a novel cancer therapy by using photohyperthermal therapy (PHT) with indocyanine green (ICG) as an optical sensitizer. ICG-Lipo is a liposomally formulated ICG derivative in which ICG is tagged with an octadeca-alkyl chain to incorporate into liposome bilayers, and contains antitumor drugs such as carboplatin and paclitaxel within the inner membrane space. The present study reported a case of feline nasal lymphoma that was treated with combination therapy of PHT with ICG-Lipo. An antitumour effect was observed, and the patient entered remission. Complications from the radiation treatment included skin burns and bleeding from the irradiated hard palate. Serious side effects related to the drugs were not observed. This report suggested that PHT using ICG-Lipo enabled efficient and safe treatment of lymphoma, and that treatment with a liposomal drug delivery system was enhanced by PHT.
Identifiants
pubmed: 32793349
doi: 10.3892/mco.2020.2107
pii: MCO-0-0-02107
pmc: PMC7418507
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
J Feline Med Surg. 2001 Dec;3(4):235-45
pubmed: 11795961
J Natl Cancer Inst. 1996 Jun 19;88(12):817-24
pubmed: 8637048
J Vet Intern Med. 2004 Mar-Apr;18(2):219-22
pubmed: 15058774
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7481-5
pubmed: 23122858
J Vet Intern Med. 2009 Mar-Apr;23(2):287-94
pubmed: 19143934
Int J Pharm. 2015 Dec 30;496(2):401-6
pubmed: 26453781
Drug Deliv. 2018 Nov;25(1):1826-1839
pubmed: 30458644
Vet Comp Oncol. 2014 Mar;12(1):52-7
pubmed: 22520498
PLoS One. 2018 Oct 4;13(10):e0204830
pubmed: 30286124
PLoS One. 2015 Apr 07;10(4):e0122849
pubmed: 25850029
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Front Pediatr. 2019 Apr 16;7:141
pubmed: 31041299
Biotechnol Adv. 2016 Sep-Oct;34(5):768-789
pubmed: 27090752
J Vet Intern Med. 2008 Jan-Feb;22(1):83-8
pubmed: 18289293
RSC Adv. 2017 Apr 3;7(32):19685-19693
pubmed: 28603607
J Feline Med Surg. 2004 Aug;6(4):245-57
pubmed: 15265480
J Vet Med Sci. 2012 May;74(5):545-51
pubmed: 22146339
J Vet Intern Med. 1988 Jan-Mar;2(1):41-6
pubmed: 3221354
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Can Vet J. 2012 Dec;53(12):1301-7
pubmed: 23729828
Bioorg Med Chem. 2014 Jan 15;22(2):721-7
pubmed: 24393719
Oncotarget. 2019 Jan 4;10(2):175-183
pubmed: 30719212
Acta Biochim Pol. 2002;49(2):387-91
pubmed: 12362980